Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC Presented ByDr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 2, DESTINY-Lung01 ConferenceESMO 2021 19 November, 2021 09:36
